Cited by 634Ubiquitin and proteasome pathwaysBRCA gene mutations in cancerCancer-related Molecular Pathways

The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation

Open access
Hashizume, Rintaro, Fukuda, Mamoru, Maeda, Ichiro, Nishikawa, Hiroyuki, Oyake, Daisuke, Yabuki, Yukari, Ogata, Haruki, Ohta, Tomohiko·2001·Journal of Biological Chemistry

Abstract

BRCA1-BARD1 constitutes a heterodimeric RING finger complex associated through its N-terminal regions. Here we demonstrate that the BRCA1-BARD1 heterodimeric RING finger complex contains significant ubiquitin ligase activity that can be disrupted by a breast cancer-derived RING finger mutation in BRCA1. Whereas individually BRCA1 and BARD1 have very low ubiquitin ligase activities in vitro, BRCA1 combined with BARD1 exhibits dramatically higher activity. Bacterially purified RING finger domains comprising residues 1-304 of BRCA1 and residues 25-189 of BARD1 are capable of polymerizing ubiquitin. The steady-state level of transfected BRCA1 in vivo was increased by co-transfection of BARD1, and reciprocally that of transfected BARD1 was increased by BRCA1 in a dose-dependent manner. The breast cancer-derived BARD1-interaction-deficient mutant, BRCA1(C61G), does not exhibit ubiquitin ligase activity in vitro. These results suggest that the BRCA1-BARD1 complex contains a ubiquitin ligase activity that is important in prevention of breast and ovarian cancer development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.c000881200

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Brca1 RING domain activity is enhanced via hetero-oligomerization with its non-catalytic partner Bard1.

    “Although the Brca1 RING domain is a different (C3HC4) subtype, functional studies have shown that its activity is enhanced via hetero-oligomerization with its non-catalytic partner, Bard1 [18].”

    From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [18]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Lorick, K. L., Jensen, J. P., Fang, S., Ong, A. M., Hatakeyama, S., and Weissman, A. M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 11364 -11369
  2. Jin, Y., Xu, X. L., Yang, M. C., Wei, F., Ayi, T. C., Bowcock, A. M., and Baer, R. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12075-12080

Cited by

Sorted by citations

Authors
Hashizume, R., Fukuda, M., Maeda, I., Nishikawa, H., Oyake, D., Yabuki, Y., Ogata, H., & Ohta, T.
Affiliations
St. Marianna University School of Medicine (JP)
Corresponding author
Ohta, Tomohiko
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2001-01
Volume
276
Issue
18
Pages
14537-14540
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2068638854
Cited by
634
References
24
Citations by year
2026: 5 · 2025: 14 · 2024: 5 · 2023: 18 · 2022: 17 · 2021: 37 · 2020: 24 · 2019: 12 · 2018: 19 · 2017: 23 · 2016: 16 · 2015: 17 · 2014: 31 · 2013: 16 · 2012: 38
FWCI
12.80
Type
journal article
Language
en
Open access
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
BRCA1, BARD1, ubiquitin ligase activity, heterodimer, breast cancer, ovarian cancer, protein-protein interaction, protein stability
MeSH terms
Breast Neoplasms, Carrier Proteins, Humans, Ligases, Mutation, Zinc Fingers, DNA, Complementary, Dimerization, BRCA1 Protein, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review